MarketCapExport financials
Landos Biopharma (LABP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Landos Biopharma Income Statement 2023-2011 | LABP
Annual Income Statement Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
48.1 M | 1.05 M | 129 M | - | - | - | - | - | - | - | - | - | - |
Shares |
6.28 M | 4.03 M | 37.6 M | 12.2 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
7.67 | 0.26 | 3.43 | - | - | - | - | - | - | - | - | - | - |
Net Income |
-21.9 M | -39.3 M | -38.4 M | -30.1 M | -13.5 M | -6.04 M | - | - | - | - | - | - | - |
Revenue |
- | - | 18 M | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-22.7 M | -40.6 M | -38.8 M | -30.7 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.2 M | 1.28 M | 394 K | 532 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-22.7 M | -40 M | -38.6 M | -30.5 M | -13 M | -5.85 M | - | - | - | - | - | - | - |
Operating Expenses |
22.7 M | 40.6 M | 56.8 M | 30.7 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
10.7 M | 14.9 M | 15.3 M | 5.34 M | 1.48 M | 1.14 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Landos Biopharma
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
6.21 M | 6.21 M | 6.21 M | 64.8 M | 4.03 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 40 M | 33.6 M | 26.1 M | 12.8 M | 12.3 M | 12.1 M | 11.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-8.9 M | -5.86 M | -3.92 M | -6.03 M | - | -7.9 M | -11.3 M | -14.9 M | - | -12.6 M | 4.1 M | -9.82 M | - | -8.23 M | -4.78 M | -5.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | 18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.3 M | -5.2 M | -4.44 M | -6.48 M | - | -7.83 M | -11.3 M | -15 M | - | -12.4 M | 3.88 M | -9.9 M | - | -8.42 M | -5.09 M | -5.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
398 K | -661 K | 517 K | 445 K | - | -67 K | -18 K | 89 K | - | -201 K | 215 K | 82 K | - | 189 K | -311 K | -26 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-9.3 M | -5.2 M | -4.44 M | -6.48 M | - | -7.83 M | -11 M | -14.6 M | - | -12.3 M | 3.98 M | -9.86 M | - | -8.32 M | -5.02 M | -5.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
9.3 M | 5.2 M | 4.44 M | 6.48 M | - | 7.83 M | 11.3 M | 15 M | - | 12.4 M | 14.1 M | 9.9 M | - | 8.42 M | 5.09 M | 5.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
6.14 M | 2.14 M | 1.98 M | 3.15 M | - | 2.97 M | 4.66 M | 4.15 M | - | 3.06 M | 2.6 M | 2.65 M | - | 1.45 M | 1.36 M | 1.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Landos Biopharma (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
